Grid Dynamics Culture Grid Dynamics Investor presentation Nasdaq: GDYN | Q2 2025 NASDAQ: GDYN © 2024 Grid Dynamics Holdings, Inc. All rights reserved. Grid Dynamics / Q4 and Full Year 2024 Disclaimer Forward-looking statements This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results of Grid Dy ...

First Solar Q2'25 Earnings Call July 31, 2025 | Important Information Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning: demand for solar technology ...

Q4 FY2025 Earnings July 31, 2025 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial m ...

Financial Performance & Outlook - Total revenue for 2025 is projected to be between $352 million and $357 million, representing an 8.1% increase at the midpoint compared to $328 million in 2024[9] - Adjusted EBITDA for 2025 is guided between $113 million and $118 million, a 21.6% increase at the midpoint from $95 million in 2024[9] - Capital expenditures, net of government grant reimbursements, are expected to be between $260 million and $290 million, a decrease of 8.3% from $300 million in 2024[9] - Adjusted EBITDA for the three months ended June 30, 2025, was $28388 thousand with a margin of 32%, compared to $23289 thousand and a 27% margin for the same period in 2024[36] Glo Fiber Expansion Markets - Glo Fiber added 5,700 new subscribers[5] - Glo Fiber expanded by over 16,000 new passings[5] - Glo Fiber revenue experienced a 40.5% growth[5] Broadband Metrics - Broadband average revenue per user (ARPU) in Glo Fiber Expansion Markets was $76.72 in Q2 2025, compared to $77.56 in Q2 2024[37] - Total broadband revenue increased from $39816 thousand in Q2 2024 to $44770 thousand in Q2 2025[37] - Total broadband revenue generating units (RGU) increased from 162,577 in Q2 2024 to 185,293 in Q2 2025[37] Commercial Fiber - The company had another record quarter for Commercial Fiber sales bookings[5]

Q2 2025 Financial Performance - Illumina's Q2 2025 revenue reached $1.06 billion, a decrease of 3% year-over-year (YoY) on both a constant currency (CC) and reported basis[7] - The non-GAAP operating margin for Q2 2025 was 23.8%[7] - Non-GAAP diluted earnings per share (EPS) for Q2 2025 stood at $1.19[7] Regional Revenue Performance - Americas region generated $586 million in revenue, a decrease of 5% YoY CC and 6% YoY reported[7] - Europe's revenue was $310 million, an increase of 6% YoY CC and 7% YoY reported[7] - Asia Pacific, Middle East, and Africa (AMEA) region contributed $100 million, a decrease of 14% YoY CC and 15% YoY reported[7] - Greater China's revenue was $63 million, a decrease of 14% YoY CC and 15% YoY reported[7] NovaSeq X Transition - NovaSeq X accounted for over 50% of high-throughput (HT) revenue and over 75% of HT Gigabases (Gb) shipped in Q2 2025[22] - NovaSeq X consumables revenue is targeted to represent approximately 50% of HT revenue by the end of 2025[22] - NovaSeq X is targeted to represent approximately 75% of HT Gb shipped towards the end of 2025[22] Acquisition of SomaLogic - Illumina announced the acquisition of SomaLogic for $350 million in cash, payable at closing, with up to $75 million in near-term revenue performance-based milestones and potential performance-based royalties[15] - The acquisition is projected to close in the first half of 2026, pending regulatory clearance[14] - SomaLogic is expected to become profitable in 2027 on a non-GAAP operating income basis, with non-GAAP operating margins aligning with Illumina's in 2028[15] Financial Guidance - Illumina's FY25 revenue guidance indicates a growth of 0% to 2%, with an FX benefit of approximately 20 bps for the rest of the world, and a revenue between $190 million and $210 million for Greater China[35] - Q3 2025 revenue guidance indicates a decline of 2.5% to 1.5%, with an FX benefit of approximately 60 bps, implying a reported revenue of $1.06 billion to $1.07 billion[35]

Perkinamine® Reliability Breakthrough - The company's thin-film devices with second-generation proprietary encapsulation barrier successfully passed the Telcordia GR-468 85/85 environmental stress test, validating long-term reliability[6] - Absorbance measurements showed only a 1.6% average loss after 1,000 hours under 85°C and 85% relative humidity, exceeding Telcordia GR-468 requirements[7,8] - The oxygen transmission rate (OTR) of the fourth-generation atomic layer deposition (ALD) encapsulation material is 1.4 × 10⁻⁶ g/m²/day, approaching the measurement limit and far exceeding the "gold-box" standard of 7 × 10⁻⁶ g/m²/day[9,14] Commercial Impact & Next Steps - Positive reception from key customers, increasing industry confidence in materials readiness after sharing 85/85 success results[10,11] - The company is preparing the fourth-generation encapsulation material for its next-release back-end-of-line (BEOL) Process Design Kit (PDK) for integration into silicon photonics foundries[14] - The next step is to demonstrate reliability on devices in partnership with customers, focusing on continuous improvement of materials, process, and encapsulation[13] Market & Strategy - The company is focusing on execution and planning for production scale to seize growth opportunities presented by the AI market[15] - Co-Packaged Optics (CPO) is emerging as a new market requiring high density ports, high bandwidth (400G+), and low power, which is an excellent fit for Perkinamine® technology[17,21] - The company reaffirms its expectation to have 3-5 customers in Stage 3 by year-end 2025[26]

Q2 2025 Key Accomplishments - Riot acquired an additional 238 acres at Corsicana, increasing the total acreage footprint to 858 acres[17] - Bitcoin Mining operations achieved a 50% gross margin[17] - The company's all-in power cost was $0.035 per kWh, and the hash cost was $25/PH/s/day[17] - Riot ended Q2 2025 with 19,273 BTC and $330 million in cash[18] - The company sold 1,371 BTC at an average price of $96,136 per BTC, generating proceeds of $132 million[18] Q2 2025 Financial Update - Riot produced 1,426 BTC in Q2 2025, averaging 15.7 BTC per day[22] - The company held 19,273 BTC valued at $2.1 billion, representing a $479 million increase[22] - Total revenue was $153 million, with $140.9 million from Bitcoin Mining, a 119% increase compared to Q1 2024[22] - Net income was $219.5 million, including a $470.8 million unrealized gain on bitcoin held[22] - Power curtailment credits amounted to $8.3 million[22]

Financial Performance - Edison International's Q2 2025 GAAP EPS was $0.89, while Core EPS was $0.97[5] - The company reaffirmed its 2025 Core EPS guidance of $5.94–6.34[5,6], which includes 44¢ from the TKM settlement (30¢ true-up + 14¢ interest reduction)[23] - Edison International reiterated a 5–7% Core EPS Compound Annual Growth Rate (CAGR) from 2025 to 2028, projecting EPS of $6.74–7.14 in 2028[5,6] - Year-to-date 2025 Core EPS was $2.34, a decrease compared to $2.37 in YTD 2024[31] Regulatory Updates and Capital Investments - A proposed decision for the 2025 General Rate Case (GRC) was issued on July 28, supporting significant capital investments while considering affordability[7] - The GRC proposed decision includes over 1,800 miles of grid hardening, shifting approximately 400 miles to covered conductor from targeted undergrounding[8] - The company anticipates investing $6.2 billion to reduce wildfire risks associated with utility equipment[14] - Edison International projects approximately 6–8% rate base growth from 2023 to 2028, driven by wildfire mitigation and grid work, resulting in a rate base of $49.4 billion in 2025, $53.0 billion in 2026, $56.8 billion in 2027 and $60.6 billion in 2028[20] Wildfire Mitigation and Cost Recovery - SCE plans to launch a Wildfire Recovery Compensation Program, with Eaton Fire investigations ongoing[5] - The company is requesting recovery of $5.4 billion of costs related to the Woolsey fire and $84 million in restoration costs[33,35] - Edison International has completed approximately $1.6 billion in securitizations of AB 1054 capital expenditures[42]

Financial Performance - IDACORP's net income for the three months ended June 30, 2025, was $95781 thousand, compared to $89520 thousand for the same period in 2024[13] - Diluted earnings per share increased from $1.71 in Q2 2024 to $1.76 in Q2 2025[13] - For the six months ended June 30, 2025, net income was $155428 thousand, up from $137693 thousand in the first half of 2024[13] - Diluted earnings per share for the first six months of 2025 were $2.87, compared to $2.67 in the same period of 2024[13] Load and Customer Growth - The 2025 Integrated Resource Plan (IRP) forecasts a 5-year annual retail sales growth rate of 8.3% and an annual peak growth rate of 5.1%[14] - The 20-year forecasted annual growth rate for retail sales is 2.7% and for annual peak is 1.9%[14] - Customer growth for the twelve months ended June 30, 2025, was 2.5%[17] Capital Projects and Resource Planning - The Boardman-to-Hemingway (B2H) transmission line project broke ground in June 2025, with an expected in-service date in late 2027; Idaho Power's interest in B2H is approximately 45%[22, 25] - The 2025 IRP includes converting Valmy units 1 and 2 from coal to natural gas in Summer 2026[26] - The 2025 IRP preferred portfolio includes the need for 450 MW of new gas resources in 2029 and 2030 and 355 MW of peak capacity resources in 2028 and 2029[27] Regulatory and Financial Matters - Idaho Power filed a general rate case with the IPUC on May 30, 2025, requesting a $199.1 million, or 13.09%, increase in total Idaho-jurisdictional revenue, effective January 1, 2026[32] - As of June 30, 2025, Idaho Power had $400 million and IDACORP had $100 million net balance available from revolving credit facilities[34] - IDACORP has an At-the-Market Offering Program with $143.5 million net proceeds available as of June 30, 2025[34] - IDACORP entered into Forward Sale Agreements that could yield $560.4 million, settled by November 9, 2026[37] - IDACORP's earnings per share guidance for 2025 is $5.70 – $5.85 per diluted share[39]

Financial Highlights - MindMed reported cash, cash equivalents, and investments of $237.9 million as of June 30, 2025[11], which is expected to fund operations into 2027 and at least 12 months beyond the first Phase 3 topline data readout in GAD[12, 15] - The company has a credit facility of up to $120 million, with $42 million outstanding as of June 30, 2025[63] - Operating expenses for the second quarter of 2025 totaled $40.9 million, including $29.8 million for R&D and $11.1 million for G&A[63, 66] - MindMed completed a $250 million equity investment[15, 63] Clinical Development - MM120 - The company's lead clinical program, MM120 ODT, is in three Phase 3 studies targeting Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)[11] - Three Phase 3 topline readouts are anticipated in 2026: one in the first half for GAD (MM120-300) and two in the second half for GAD (MM120-301) and MDD (MM120-310)[14, 64] - MM120 Phase 2b trial demonstrated a 21.9-point improvement on the HAM-A at Week 12 (p=0.003) and a 48% remission rate in participants at Week 12[34] - MM120 Phase 2b also showed a 18.7-point improvement in MADRS score at Week 12, with a 6.4-point improvement over placebo (p<0.01)[38] Market Opportunity - 26 million U S adults live with GAD and 41 million U S adults live with MDD[20] - Approximately 50% of GAD patients fail first-line pharmacological treatments[20] - Approximately 2/3 of MDD patients do not achieve remission after first-line therapy, and 30% fail by 2+ lines of therapy[20] - Surveyed providers indicated that 62% of all psychiatric providers and 78% of interventional psychiatric providers believe the availability of psychedelics for GAD and MDD will change their approach to treatment[24]